Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

NCT04421222 is registered in ClinicalTrials.gov with ESSA Pharmaceuticals as lead sponsor.

NCT NCT04421222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04421222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
Lead sponsor
ESSA Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
June 23, 2020
Completion date
December 3, 2024
Enrollment
71 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer